AnaptysBio, Inc. - Common Stock (NQ:ANAB)

48.28 -0.36 (-0.74%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Top movers in Monday's after hours session ↗

September 21, 2026

Via Chartmill

AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup ↗

August 19, 2026

Via Chartmill

AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen ↗

May 02, 2026

Via Chartmill

Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗

April 20, 2026

Via Chartmill

What's going on in today's session ↗

April 20, 2026

Via Chartmill

ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup ↗

January 23, 2026

Via Chartmill

ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment ↗

January 17, 2026

Via Chartmill

ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗

November 21, 2025

The dispute centers around Tesaro’s participation in PD-1 trials.

Via Stocktwits

Topics Lawsuit

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗

September 30, 2025

Via Stocktwits

These stocks are gapping in today's session ↗

April 20, 2026

Via Chartmill

Top movers in Monday's pre-market session ↗

April 20, 2026

Via Chartmill

What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally ↗

January 11, 2026

This biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price gains.

Via The Motley Fool

Topics Regulatory Compliance

What Investors Should Know About a $163K AnaptysBio Insider Sale ↗

January 11, 2026

This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Why Is Eli Lilly’s Stock Slipping Premarket? ↗

September 17, 2025

Via Stocktwits

Analyst Expectations For AnaptysBio's Future ↗

August 07, 2025

Via Benzinga

Analyst Expectations For AnaptysBio's Future ↗

July 24, 2025

Via Benzinga

AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum ↗

December 20, 2025

AnaptysBio (ANAB) meets the Minervini Trend Template, showing a powerful technical uptrend backed by accelerating earnings and revenue growth momentum.

Via Chartmill

AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗

November 22, 2025

AnaptysBio (ANAB) is a high-growth biotech stock with a strong technical uptrend, surging revenue, and impressive relative strength.

Via Chartmill

ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗

November 13, 2025

ANAB stock shows explosive revenue growth and strong technical setup, making it a top momentum pick for biotech investors.

Via Chartmill

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗

November 10, 2025

AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs.

Via Benzinga

Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗

November 10, 2025

The company was working on a treatment for ulcerative colitis, using a relatively different approach.

Via Investor's Business Daily

Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗

October 01, 2025

Markets closed in the green on Tuesday, undeterred by the looming U.S. government shutdown. Pfizer surged nearly 7% on a political deal, while CoreWeave soared after signing a multibillion-dollar AI...

Via Chartmill

Topics Artificial Intelligence

Here are the top movers in Tuesday's session. ↗

September 30, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗

September 30, 2025

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

September 30, 2025

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 29, 2025

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.

Via Benzinga

AnaptysBio (ANAB) Q2 Revenue Jumps 103% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗

June 04, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.